Creative Biolabs rAb Blog

Menu

Skip to content
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News

Therapeutic Antibodies

Creative Biolabs offers a full range of therapeutic antibodies currently available for research of a wide variety of diseases.

Learn More

Hi-affi™ Recombinant Antibodies

With optimized library construction and screening processes using hybridoma or phage display technology, We have developed proprietary procedures for Hi-Affi™ recombinant antibody production.

Learn More

Single-domain Antibodies

SdAbs are single-domain antibodies (SdAbs) derived from the variable regions of heavy chain of Camelidae immunoglobulins, also called VHHs. Creative Biolabs provides the most complete collection of SdAb products the world has ever had.

Learn More

Antibody Engineering Service

With our unique platform, Creative Biolabs provide antibody engineering service, especially glycoengineering for our clients all over the world.

Learn More
02Oct/23

Researchers Revealed the Feasibility and Clinical Prospects of Targeting SLC7A11 for the Treatment of Osteosarcoma

October 2, 2023Cancer ImmunotherapyOsteosarcoma, SLC7A11biorab

Osteosarcoma (OS) is the most common malignant bone tumor, primarily affecting adolescents. In the 1970s, the clinical use of chemotherapy in conjunction with surgical resection significantly improved the five-year survival rate ofRead More…

02Sep/23

Controlling Widespread Neutralizing Antibodies Produced in Post-Treatment Controllers Promotes Long-Term Remission of HIV-1 Infection

September 2, 2023News, Therapeutic Antibody R&DHIV-1 Infection, Neutralizing Antibodiesbiorab

Some HIV-1 carriers who received early antiretroviral therapy (ART) for several years can maintain long-term control over the virus after treatment interruption. However, the mechanism behind this post-treatment control is not fullyRead More…

01Aug/23

Scientists Identify Special Genes Capable of Producing a Large Number of Key Antibodies

August 1, 2023Cancer Immunotherapy, Therapeutic Antibody R&DAntibody Productionbiorab

Cellular secretions play various crucial roles within the body. However, methods to connect this functional information with surface markers and the transcriptome have been lacking. In a recent research paper published inRead More…

14Jul/23

Targeting Integrins for the Treatment of Drug-Resistant Acute Myeloid Leukemia

July 14, 2023Cancer ImmunotherapyAcute Myeloid Leukemia, Integrinbiorab

Acute myeloid leukemia (AML) remains highly resistant to treatment with a high relapse rate, necessitating the development of new therapeutic strategies. Integrin-targeted therapy, which has been extensively studied in solid tumors andRead More…

29Jun/23

The Roles of Loss of CXCR2 Expression/Activity in Melanoma Tumorigenesis

June 29, 2023Cancer ImmunotherapyCXCR2, Melanoma Tumorigenesisbiorab

Chemokines and their receptors have been shown to play crucial roles in regulating tumor growth, progression, metastasis, and response to immunotherapy. Initially known for their role as chemoattractants in guiding leukocyte migration,Read More…

12May/23
Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance

Targeting PD-L2-RGMb Promises to Enhance the Efficacy of Cancer Immunotherapy

May 12, 2023News, Therapeutic Antibody R&DCancer Immunotherapy, Targeting PD-L2-RGMbbiorab

Immunotherapy has revolutionized the treatment of many cancer types. However, for reasons that remain poorly understood, not all patients respond equally from these potent therapies. In a recent study, researchers from HarvardRead More…

30Apr/23
Recombinant Antibody

Scientists Reviewed the Advances, Challenges and Countermeasures in Immunotherapy of Gastrointestinal Tumors

April 30, 2023Cancer Immunotherapy, NewsGastrointestinal Tumor, immunotherapybiorab

The morbidity and mortality of intestinal tumors are among the top malignant tumors, and they are major diseases that seriously threaten people’s health. The prognosis for some patients with gastrointestinal malignancies hasRead More…

12Mar/23

Released! Mechanisms Behind Immune Cells’ Responses to Cancer Cell Mutations

March 12, 2023Cancer Immunotherapy, NewsCancer Immunotherapybiorab

Neoantigens are peptides derived from nonsynonymous mutations in human leukocyte antigens (HLAs) that are recognized by antitumor T cells. The large diversity of HLA alleles and limited clinical samples often narrow scientists’Read More…

22Feb/23

The Ineffectiveness of Cancer Immunotherapy May Be Due to the Lack of Specific Key Immune Cells in Patients

February 22, 2023Cancer ImmunotherapyCancer Immunotherapybiorab

Nowadays, immunotherapy has dramatically changed the care of cancer patients. In the case of patients with advanced melanoma, one of the most lethal cancers of human skin, the 5-year survival rate hasRead More…

02Jan/23

Scientists Discovered the Key Molecule Triggering Cancer Metastasis

January 2, 2023Cancer Immunotherapy, NewsCancer Immunotherapybiorab

Many cancer cells never leave their original tumor tissue. Some cancer cells have evolved the ability to migrate to other tissues, but they will become dormant once they are unable to formRead More…

Posts navigation

  • 1
  • 2
  • 3
  • …
  • 5
  • Next »

Categories

  • Antibody Engineering R&D
  • Cancer Immunotherapy
  • News
  • Recombinant Antibody R&D
  • Therapeutic Antibody R&D

Recent Posts

  • Researchers Revealed the Feasibility and Clinical Prospects of Targeting SLC7A11 for the Treatment of Osteosarcoma
  • Controlling Widespread Neutralizing Antibodies Produced in Post-Treatment Controllers Promotes Long-Term Remission of HIV-1 Infection
  • Scientists Identify Special Genes Capable of Producing a Large Number of Key Antibodies
  • Targeting Integrins for the Treatment of Drug-Resistant Acute Myeloid Leukemia
  • The Roles of Loss of CXCR2 Expression/Activity in Melanoma Tumorigenesis

Archives

Contact Us

USA – UK

Copyright © Creative Biolabs rAb Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Therapeutic Antibody R&D
  • Recombinant Antibody R&D
  • Antibody Engineering R&D
  • News